Samuel Kintz, PRESIDENT AND CEO at Enliven Therapeutics, Inc. (ELVN), sold 27,142 shares at $27.51 ($747K) on 2024-10-04, disclosed to the SEC on 2024-10-08.
Scheduled sale ($747k) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $27.51 | 12,206 | $336K | 45.0% |
| 2 | $27.51 | 12,206 | $336K | 45.0% |
| 3 | $27.50 | 2,730 | $75K | 10.1% |
| Total | $27.51 avg | 27,142 | $747K | 100% |
| Filing → |
| ELVN | SELL | 2025-09-30 | $74K | — | Filing → |
| ELVN | SELL | 2025-09-25 | $56K | — | Filing → |
| ELVN | SELL | 2025-09-19 | $116K | — | Filing → |